How ASGCT and OTXL Are Working to Revive Shelved Cell and Gene Therapies
The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have launched CGTxchange, an AI‑driven matchmaking platform designed to revive cell and gene therapies that were shelved for ultra‑rare diseases. By aggregating confidential and public data into structured asset cards, the service helps investors, CROs, and patient groups identify viable development pathways. The platform also offers deferred‑cost manufacturing models to lower financial risk for smaller sponsors. Ultimately, CGTxchange aims to turn clinically successful but commercially stalled therapies into accessible treatments for patients.
The Evolving Biopharma Regulatory Landscape: Q&A with Harpreet Singh, MD
Harpreet Singh, former FDA oncology division director and now chief medical officer at Precision for Medicine, explains how the FDA is reshaping biopharma regulation through a shift to single pivotal trials for high‑risk cancers, the expanding but opaque National Priority...
How Real-World Evidence Is Shaping Inclusive Clinical Trials with Takeda CMO Dr. Awny Farajallah — Episode 257
In the latest Xtalks Life Science Podcast, Takeda CMO Dr. Awny Farajallah explains how real‑world evidence (RWE) is reshaping clinical trial design to be more inclusive and diverse. He highlights the use of RWE in rare‑disease programs such as narcolepsy...
Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting
Junevity will present pioneering in‑vivo data showing an siRNA therapeutic can restore global gene networks to a healthier state. Co‑founder Dr. Janine Sengstack will share results from diabetic mouse studies and safety data in rats and non‑human primates, marking the...
The Most Expensive Drugs on the Market in 2026 — and Why They Cost So Much
In 2026 the United States market is dominated by ultra‑high‑priced one‑time gene and cell therapies, with Lenmeldy leading at $4.25 million per patient. Other top‑tier products include Hemgenix ($3.5 M), Elevidys ($3.2 M), Lyfgenia ($3.1 M) and Skysona ($3 M). Reuters notes the median list...
Matt Kaeberlein's New Longevity Science Podcast / Youtube Channel (May, 2026)
Dr. Matt Kaeberlein’s Longevity Science podcast provides a biochemistry‑focused audit of the burgeoning peptide market, clarifying that true peptides are short amino‑acid chains and excluding compounds like NAD+ and rapamycin. He evaluates leading peptides—synthetic mitochondrial agent Elamipretide and the popular...
Do You Think the CNPV Program Has Delivered on It's Promises?
Harpreet Singh, MD, chief medical officer at Precision for Medicine, evaluates the FDA's Commissioner’s National Priority Voucher (CNPV) program, noting it speeds regulatory review after pivotal trials are completed. She highlights voucher use across oncology, antibiotics, pain management and psychedelics,...
IBio’s Global Clinical Trial Strategy for Advancing Next-Gen Obesity Drugs
iBio is advancing next‑generation obesity therapeutics that go beyond GLP‑1 weight‑loss drugs, focusing on muscle preservation, durability, tolerability, and cardiometabolic complications. The company secured Australian regulatory clearance for a Phase I trial of IBIO‑600, a long‑acting anti‑myostatin antibody designed for infrequent...
Peptides / Bioregulators
Therapeutic peptide development has accelerated over the past decade thanks to new synthesis, modification, and analytical platforms, positioning peptides as a fast‑growing drug class. While FDA‑approved peptides remain limited to GLP‑1 analogues and a handful of niche indications, a flood...
World Blood Cancer Day 2026: New FDA Approvals and Phase III Readouts
World Blood Cancer Day 2026 highlights a projected 180,000 new U.S. blood‑cancer cases, underscoring the disease’s growing burden. The FDA granted several approvals, including an all‑oral decitabine/cedazuridine‑venetoclax regimen for older AML patients and Beqalzi for relapsed mantle‑cell lymphoma. Janssen’s Tecvayli...
2g/Day of DHA for 2 Years Has No Impact on Cognition or Hippocampal Volume (PreventE4)
The PreventE4 trial tested 2 g per day of DHA for two years in cognitively normal APOE ε4 carriers, achieving a significant rise in the CSF DHA‑to‑arachidonic‑acid ratio. Despite this biochemical target engagement, magnetic‑resonance imaging showed no change in hippocampal volume or...
Fragments in the Clinic: VVD-214
Vividion’s covalent WRN inhibitor VVD‑214 evolved from a vinyl‑sulfone fragment hit (compound 1a) to a clinically viable candidate through a series of empirical SAR steps. Introducing a methyl group (2a) boosted stability and sub‑micromolar cellular potency, while a tert‑butyl cyclopentyl...
Clinical Trial Endpoint by Counting Hairs - Story of Clinical Trials in Androgenetic Alopecia (Hair Loss)
Veradermics announced that its extended‑release oral minoxidil (VDPHL01) met primary endpoints in a pivotal Phase 2/3 trial of 519 men with androgenetic alopecia. The study showed a mean increase of 30.3 hairs/cm² (once‑daily) and 33.0 hairs/cm² (twice‑daily) in non‑vellus target‑area hair...
World Schizophrenia Day 2026: New Data, Tests & Treatment Targets
On World Schizophrenia Day, new data reveal a rising US prevalence of about 3.07 million adults and a 60% increase in diagnoses among youth. The article spotlights several mid‑ to late‑stage drug programs—a muscarinic M1/M4 agonist, a PDE10A inhibitor, and a...
Deep Generative Molecular Design and Its Value in Modern Drug Discovery (Paper Feb 26)
The February 2026 review maps the rapid rise of deep generative molecular design in drug discovery, arguing that AI is moving from virtual screening toward the creation of new, testable drug hypotheses. It categorises the field into three technical families—graph‑based...
Eli Lilly’s Triple Agonist Retatrutide Hits 28.3% Mean Weight Loss in TRIUMPH-1 Phase 3, Blowing Past Tirzepatide Benchmarks & Rewriting...
Eli Lilly’s triple‑agonist retatrutide delivered a 28.3% mean body‑weight reduction (about 70 lb) after 80 weeks in the phase‑3 TRIUMPH‑1 trial, far surpassing tirzepatide’s ~22.5% peak. The 12 mg dose drove 62.5% of participants to lose at least 25% of their weight, with 27.2%...
Inocras Announces ASCO 2026 Online Publication: Whole-Genome HRD Phenotyping as a Predictor of PARP Inhibitor Benefit in First-Line Maintenance High-Grade...
Inocras announced that whole‑genome sequencing‑based HRD phenotyping predicts benefit from PARP inhibitor maintenance in high‑grade serous ovarian cancer. In a real‑world study of 84 patients at Severance Hospital, HRD‑positive tumors had a median progression‑free survival of 27.5 months versus 12.0...
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
Galderma announced that the U.S. FDA has approved Differin Epiduo® Acne Gel for over‑the‑counter sale to consumers aged 12 and older. The switch moves a prescription‑strength combination of adapalene 0.1% and benzoyl peroxide 2.5% into the retail market, leveraging more than...
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (Mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite Bioscience announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat) to treat anaemia in adults with transfusion‑dependent or non‑transfusion‑dependent alpha‑ or beta‑thalassaemia. The approval follows positive CHMP opinion and data from the Phase 3 ENERGIZE and ENERGIZE‑T...
Cyclarity Therapeutics Reports Safety Data for 7-Ketocholesterol Clearance
Cyclarity Therapeutics reported first clinical evidence that its AI‑engineered cyclodextrin drug, UDP‑003, can safely bind and promote urinary excretion of 7‑ketocholesterol, a toxic oxysterol linked to atherosclerosis. The Phase 1 safety trial demonstrated favorable pharmacokinetics and pharmacodynamics, with no serious adverse...
Retatrutide Results Suggest a Change in the Order of Things
Eli Lilly’s phase‑3 trial of retatrutide, a triple‑agonist peptide, showed patients with severe obesity lost an average of 30% of body weight over 80 weeks, a result comparable to bariatric surgery. The study also reported significant improvements in cardiometabolic markers such...
Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?
The FDA is increasingly willing to approve drugs based on a single pivotal trial, a shift described by former FDA Oncology Division Director Harpreet Singh as an evolution rather than a revolution. In oncology, especially for rare, life‑threatening cancers, a...
Peanut OIT Safety in Preschoolers: A Slow-Dosing Strategy
A new randomized controlled trial in The Lancet shows that a slow up‑dosing schedule combined with a low maintenance dose makes peanut oral immunotherapy (OIT) safer for preschool‑aged children. The study enrolled roughly 150 participants aged 12‑48 months and found...
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
Scribe Therapeutics received clearance from Australia’s TGA to start a first‑in‑human Phase 1 study of STX‑1150, an in‑vivo CRISPR‑based therapy that epigenetically silences PCSK9 to lower LDL‑C. The open‑label, single‑ascending‑dose trial will enroll up to 64 high‑risk hypercholesterolemia patients across Australia...
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
Merck has dosed the first patient in the Phase 3 PROCEADE‑CRC‑03 trial of Precem‑TcT, the company’s inaugural anti‑CEACAM5 antibody‑drug conjugate (ADC) featuring an exatecan payload for metastatic colorectal cancer (mCRC). In Phase 1, the ADC achieved a 20.7% confirmed objective response rate...
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
Bayer announced that it will unveil 16 new oncology abstracts at the ASCO 2026 meeting in Chicago, spanning prostate, breast, lung, renal‑cell, colorectal and salivary‑gland cancers. The headline presentation will feature Phase II head‑to‑head data comparing NUBEQA (darolutamide) with enzalutamide in...
Degrader–Antibody Conjugates: Can Targeted Delivery Improve Tolerability?
Degrader‑antibody conjugates (DACs) fuse small‑molecule protein degraders to targeting antibodies, aiming to deliver the degrader selectively to disease‑relevant cells. Early pre‑clinical studies show that DACs can achieve potent target knock‑down while sparing healthy tissue, translating into a markedly better safety...
What Does the Regulatory Landscape Look Like From the Other Side of FDA?
Harpreet Singh, MD, former FDA Oncology Division Director and now chief medical officer at Precision for Medicine, explains that industry sponsors find the oncology regulatory landscape more navigable when they leverage insider experience. He stresses three pillars: early and frequent...
MHRA Proposes New Regulatory Pathway for Rare Disease Therapies
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on a new, technology‑agnostic regulatory pathway for rare disease therapies. Central to the proposal is an Investigational Marketing Authorisation (IMA) that merges clinical trial approval with a...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced FDA approval of Guardant360® Liquid CDx, the largest liquid‑biopsy panel on the market, featuring a 100‑fold expanded genomic footprint. The test merges genomic and epigenomic profiling from a single blood draw, delivering several‑fold higher circulating tumor DNA...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
IntraBio announced regulatory authorization to launch its pivotal Phase III trial of levacetylleucine (AQNEURSA) in CACNA1A‑related disorders across the United States, United Kingdom, European Union and Switzerland. The 12‑week, randomized, double‑blind, placebo‑controlled crossover study will be conducted at twelve multinational sites...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte and Genesis Molecular AI have broadened their partnership, granting Genesis access to Incyte's proprietary experimental data to train the next‑generation GEMS AI platform. The deal includes a $120 million upfront payment—$80 million in cash and $40 million in equity—plus recurring research funding....
Airway Therapeutics CEO on Rethinking Bronchopulmonary Dysplasia Trials
Airway Therapeutics is advancing zelpultide alfa, an investigational biologic aimed at preventing bronchopulmonary dysplasia (BPD) in extremely preterm infants born between 22 and 27 weeks gestation. CEO Marc Salzberg highlighted the clinical and operational hurdles of neonatal trials, including limited...
Greek Courts Deliver Landmark Justice: State Held Liable for COVID Shot Harms
Greek administrative courts have begun holding the Hellenic Republic liable for COVID‑19 vaccine injuries, ordering $324,000 in compensation to a family after a woman died from AstraZeneca‑induced thrombosis with thrombocytopenia syndrome (TTS). The decision builds on a 2025 ruling that...
Inside the Expert Network Guiding TGN-S15 to Market
Toragen’s CEO Sandra Coufal detailed the formation of a Scientific Advisory Board designed to steer the HPV‑targeted therapy TGN‑S15 through development. The board is anchored by Dr. Aldo Venuti, a leading authority on the HPV E5 protein, who supplies the rare W12...
What It Takes to Run Rare Pediatric Disease Trials Across Borders: Insights From Polaryx Therapeutics
Polaryx Therapeutics is gearing up to test its oral candidate PLX-200 in a Phase II SOTERIA basket trial for four ultra‑rare lysosomal storage disorders—CLN2, CLN3, Krabbe and Sandhoff. The FDA has granted Fast Track designation for all four indications, promising closer...
Testosterone Shots: SubQ or IM?
A 2022 head‑to‑head trial of 234 hypogonadal men compared weekly intramuscular testosterone cypionate with subcutaneous testosterone enanthate. Both routes achieved equivalent total testosterone levels, but the subcutaneous group showed significantly lower post‑therapy estradiol and hematocrit. The flatter absorption curve of...
Developing a Drug To Reverse Heart Disease
Repair Biotechnologies’ lead candidate, REP-0004, is an mRNA‑based lipid nanoparticle designed to deliver a cholesterol‑degrading protein exclusively to hepatocytes. The FDA granted the drug orphan‑drug status and the company targets a Phase 1 start by mid‑2027, pending GMP manufacturing and IND‑enabling...
Adenine Base Editing Demonstrates Profound Impact on Rare Disease
Researchers at The Jackson Laboratory used adenine base editing to repair the SCN1A R613X mutation that causes Dravet syndrome in mice. A single brain injection corrected roughly 60% of the defective DNA, restoring normal gene expression and dramatically reducing seizures....
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
The FDA has granted approval to Baxfendy (baxdrostat), AstraZeneca’s first aldosterone synthase inhibitor, for adults whose blood pressure remains uncontrolled despite existing therapies. The approval is based on the phase 3 BaxHTN trial, where a 2 mg dose lowered systolic pressure by...
Module 4, Section 3: Selectivity and Site
The fourth lecture in the Protein Structure & Target Pharmacology module examines how drug discovery teams achieve selectivity. It outlines strategies for designing ligands that discriminate across the entire proteome, within closely related protein families, and even between proteins that...
What Psychedelic Clinical Trials Could Teach Psychiatry
Treatment‑resistant depression (TRD) affects roughly one‑third of U.S. adults on antidepressants and remains a high‑need, low‑treatment area. Compass Pathways’ synthetic psilocybin, COMP360, recently achieved its primary endpoints in two Phase III trials—258 patients in COMP005 and 581 in COMP006—showing rapid, durable...
Dr. Reddy’s Laboratories Launches Its Generic Semaglutide Injection in Canada
Dr. Reddy’s Laboratories received Health Canada’s Notice of Compliance on April 28, 2026 and launched the first generic semaglutide injection in Canada, the inaugural G7 approval for a generic version of the GLP‑1 drug. The product is offered in 2 mg and 4 mg...
ENHERTU® (Fam-Trastuzumab Deruxtecan-Nxki) Approved in the US for Two New Indications for Patients with HER2-Positive Early Breast Cancer
The FDA has approved AstraZeneca and Daiichi Sankyo’s ENHERTU (fam‑trastuzumab deruxtecan‑nxki) for both neoadjuvant and adjuvant treatment of HER2‑positive early‑stage breast cancer. In the neoadjuvant setting, ENHERTU plus taxane, trastuzumab and pertuzumab achieved a 67.3% pathologic complete response, outperforming standard...
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
United Therapeutics received FDA clearance to begin the EXPRESS clinical trial of its UHeart xenotransplant, a pig‑derived heart with ten gene edits. The phase‑1/2/3 study will initially enroll up to two end‑stage heart‑failure patients, with safety and efficacy data reviewed...
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Agenus published Phase 1b data on botensilimab plus balstilimab in 19 patients with treatment‑refractory hepatocellular carcinoma who had progressed after prior immunotherapy. The combination achieved a 17% objective response rate, a 50% clinical benefit rate at 18 weeks, median progression‑free survival...
TRI-611
TRI‑611 is a CNS‑penetrant, CRBN‑mediated molecular‑glue degrader targeting ALK fusion proteins in ALK‑positive non‑small cell lung cancer (NSCLC). By recruiting a non‑G‑loop degron distal to the orthosteric site, it degrades ALK independently of the active site, sidestepping common tyrosine‑kinase inhibitor...
Clinical Trial Failures of 2026
Clinical trial success rates remain low, hovering around 5% overall, with Phase II proving especially challenging. Industry‑sponsored Phase II and III terminations have roughly doubled from 2013 to 2023, often driven by commercial strategy shifts. In 2026, several high‑profile late‑stage...
Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
The FDA has approved AstraZeneca’s Fasenra (benralizumab) for patients 12 and older with hypereosinophilic syndrome (HES), adding a rare‑disease indication to a drug already used for severe eosinophilic asthma. The approval rests on the Phase III Natron trial, which showed a...
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech...
Bristol Myers Squibb announced a $15.2 billion strategic licensing agreement with China’s Hengrui Pharma, front‑loading $600 million and targeting faster trial timelines. FDA Commissioner Marty Makary resigned, leaving acting head Kyle Diamantas—who lacks drug‑review experience—in charge and heightening regulatory uncertainty. Regenxbio reported clean...